cyrilzakka/clinical-trials huggingface dataset:
Renal Considerations in the Heat Stress Recommendations

An epidemic of chronic kidney disease is occurring in laborers who undertake physical work outdoors in hot conditions. The reason for this is unknown, but may be related to kidney dysfunction caused by increases in body temperature and dehydration. The current heat stress recommendations for workers were not developed with regards for kidney health. The purpose of this study is to determine if the current recommendations protect against kidney dysfunction.


Eligibility Criteria:
Inclusion Criteria:

* Men and women
* 18-44 y old
* Body mass index ≤35.0 kg/m2
* Self-reported to be healthy.

Exclusion Criteria:

* Not within defined age range
* Estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73m2
* Deemed highly active according to the physical activity questionnaire (i.e., \>3500 MET\*min/wk)
* Body mass index \>35.0 kg/m2
* Current or history of any renal disease, heart disease, stroke, immune or autoimmune disease, and/or gastrointestinal disease/surgery
* Hypertension during screening (systolic blood pressure \>139 or diastolic blood pressure \>89)
* Using medications that blunt the physiological response to exercise (e.g., beta blockers)
* Prescription medication with a known side effect of impaired temperature regulation or fluid balance (e.g., diuretics)
* Positive pregnancy test at any time during the study or breast feeding
* Current tobacco or electronic cigarette use or consistent use within the last 2 years
* Inability to safely complete the peak oxygen uptake test
Evaluation of the Role of Poisoning Severity Score, Serum Procalcitonin and C-reactive Protein in Acute Hydrocarbon Intoxicated Cases Admitted to the Poison Control Center Ain Shams University Hospitals

Hydrocarbons are a primary energy source in modern society. They are present in many common household and occupational products, including motor fuels, paint thinners, cleaning agents, lotions, and industrial solvents. Unfortunately, these products are also used as agents of abuse and typically inhaled .

They are derived mainly from petroleum (kerosene, gas, naphtha) or wood (turpentine, pine oil). They can be found in liquid, gas, or solid form depending on their properties. All hydrocarbons can be toxic, but aromatic (ring-shaped) and halogenated hydrocarbons typically have more severe toxicity .

Toxicity occurs in various ways including through inhalation, ingestion, aspiration, and dermal exposure. Frequently, these exposures occur during attempted recreational use of the substances and sometimes for self-injurious behavior


Eligibility Criteria:
Inclusion Criteria:

Patients of both sexes admitted to the Poison control center, Ain Shams university hospitals with acute hydrocarbon toxicity during the duration from December 2023 till December 2024 with a maximum number of 60 cases within 24 hours of intoxication.

Exclusion Criteria:

Patients with these criteria will be excluded:

* Cases \> 24 hours of intoxication.
* Cases with occupational exposure to hydrocarbons.
* Pregnant females.
* Any cases received any treatment before arrival to the PCC.
* Cases suffering from cardiac, respiratory, renal, hepatic or haematological disorders.
* Cases presenting with fever.
* Cases with other causes that can increase levels of CRP \& pro-calcitonin as bacterial infection, recent major trauma, major burn ,septic shock and medullary thyroid cancer.
Nurses' Knowledge, Barriers and Practices in the Assessment of Delirium in the Intensive Care Unit

Delirium in intensive care patients is a complication associated with many adverse consequences. It negatively affects patient outcomes, is an independent predictor of mortality, prolongs intensive care unit (ICU) stay and causes cognitive impairment. It is estimated that delirium affects up to 80% of ICU patients. Unfortunately, delirium still remains undiagnosed in many cases. Due to the high prevalence of this complication in critically ill patients, it is important to implement an effective management protocol to prevent delirium.

Nurses' knowledge of delirium, learning about nursing practices and identifying barriers to delirium assessment, may be an important basis for early recognition and the creation of procedures for delirium prevention in the intensive care unit.

The survey questionnaire is aimed at nurses working in the intensive care unit.

First, respondents are asked to answer questions on socio-demographic data. Then, two questionnaires were used to conduct the study:

1. The Nurses' Knowledge of Delirium questionnaire.

   The questionnaire consists of two parts:
   * The first part deals with questions related to the definition of delirium and the tools used to detect specific conditions.
   * In the second part, participants are asked to answer questions about delirium and its associated risk factors by ticking respectively "agree", "disagree" or "not sure" to a series of 28 statements.

   Fourteen of these statements relate to delirium, its symptoms and management, and 14 relate to risk factors for delirium.
2. Nursing Practices and Perceptions Towards Delirium in the Intensive Care Unit questionnaire.

The questionnaire consists of two parts:

* The first part consists of questions about sedation and delirium assessment.
* The second part deals with practices/opinions about delirium and its assessment, including identification of potential barriers to delirium assessment

Consents were obtained from the authors for the use of both research tools. Completion of the questionnaire is voluntary, anonymous and equivalent to giving informed consent to participate in the study.

Eligibility Criteria:
Inclusion Criteria:

* Nurses,
* ICU staff.

Exclusion Criteria:

* Other medical staff,
* children's ICU staff,
* nurses working in other departments.
Physiological Study to Assess Mechanism of Action of MOBIDERM® in Lower-limb Lymphedema Patients

MOBIDERM® demonstrated his interest through clinical studies on the treatment of lower or upper limb lymphedema (Mestre et al 2017; Quéré et al. 2014). This CE (Conformity European)-marking device is well established both in ambulatory and hospitalisation. Nevertheless, the mechanism of action of this device had never been confirmed and no experimental clinical studies had been performed. The hypothesis is that the MOBIDERM system creates a pressure differential between the contact zone underneath the foam cubes composing the system and their surrounding area, leading to a shear effect on the subcutaneous tissues treated.

The aim of this study is thus to assess the mechanism of action of MOBIDERM on the lymphatic system by evaluating quantitative and qualitative effects of this medical device on lymphatic system, oedema volume and cutaneous parameters in 10 lymphoedema patients during their hospitalisation for reduction phase.


Eligibility Criteria:
Inclusion Criteria:

* Primary or secondary lower limb lymphedema of stage 2 or 3 according to the criteria defined by International Society of Lymphology
* Affected leg that fits with one of the standard sizes of the Auto-Adjustable MOBIDERM® Autofit stocking provided
* Signed informed consent prior to any study-mandated procedure.

Exclusion Criteria:

* Pregnant or breastfeeding patient
* Childbearing age patient without contraception
* Intolerance to Mobiderm or known allergy to the components used
* Evolutive lower limb infection
* Acute lower limb inflammation
* Dermatological ailment oozing from the treated limb
* Severe medical condition that may interfere with the proper conduct of the study
* Advanced diabetic microangiopathy
* Limb arteritis stage III or IV
* Decompensated heart failure
* Involvement in another clinical study
* Patient mentally incapable of understanding the nature, objectives and possible consequences of the study and / or refusing to submit to the constraints of this trial
Effects of Whole-body Electromyostimulation on Golf Performance in Amateur Golfers

Golf is becoming increasingly popular in Germany. However, the biomechanical and motor challenge of golf should not be underestimated. Nevertheless, only very few amateur golfers carry out serious preparation and conditioning as part of a strength/stabilization program. The main argument for this limitation is the aspect of "limited time resources". A solution to this problem could therefore be the time-effective and highly individualizable whole-body electromyostimulation (WB-EMS) technology.

The aim of the present study is to evaluate the effectiveness of 16 weeks of WB-EMS application on trunk stability and clubhead speed in male amateur golfers in a (randomized) controlled setting.


Eligibility Criteria:
Inclusion Criteria:

* Golfhandicap ≤20,
* members of the Golfclub München-Eichenried

Exclusion Criteria:

* diseases and medication that did not allow WB-EMS training (see contraindications WB-EMS) or enable proper assessment of clubhead speed (in cases of doubt, individual medical decision),
* resistance and/or WB-EMS Training during the last 6 months,
* more than two expected missed WB-EMS sessions
Clinical Trial of Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease

The hypothesis of this study is that DiaoShi Jifa reduces the symptoms, such as dizziness in patients with Meniere's disease.

Created by Dr. Diao, DiaoShi Jifa is a well-known traditional Chinese Medicine approach to treat dizziness in patients with chronic diseases. The investigators designed this randomized clinical trial to examine whether Diaoshi Jifa significantly decreases dizziness in patients with Meniere's disease. There are 2 arms in this trial: One arm is DiaoShi Jifa plus conventional Western medical treatment, another is conventional Western medical treatment only. The dizziness handicap inventory (DHI) will be used to evaluate the treatment effect.

Eligibility Criteria:
Inclusion Criteria:

1. Clinical diagnosis of probable Meniere's disease
2. Must be able to receive manual treatment
3. Dizziness Patients receiving other treatment longer than 5 days before entering the study.

Exclusion Criteria:

1. Patients with critical illness of internal medicine and surgery
2. Patients with spinal disease or other conditions that cannot receive manual treatment.
After-school Game-Based Physical Activity Program Improves Physical Fitness of 9-10-Year-Old Children

This study investigates the effect of an afterschool game-based physical activity program (AGPAP) on children's PF. This study was randomized controlled trial involving 120 children from a state school in Eskisehir/Turkey. The CONSORT checklist was used in this study. The sample of 9-10 years children (n = 120) was divided into groups by randomization. The intervention consisted of AGPAP. For PF, handgrip strength, curl-ups, sit-and-reach, standing long jump, and 10-meter running speed tests were applied.


Eligibility Criteria:
Inclusion Criteria:

1. being 9-10-year-old,
2. volunteering,
3. permission from the child's parents,
4. not having any amputations or permanent disabilities in their bodies,
5. not having chronic or acute diseases,
6. not using a support device.

Exclusion Criteria:

1. any discomfort during measurements,
2. the child does not want to participate in the measurement,
3. the child does not participate in the practices due to any disability or discomfort,
4. not reaching 80% participation in the program.
Morphological and Functional Evaluation of Adult Flat Foot Before and After Corrective Surgery

Morphological weight bearing computed tomography parameters and gait analysis can implement the evaluation of the flat foot. Weight bearing CT is useful to verify the severity of the 3D deformities typical of flat foot, while kinematic and kinetic variables of gait is able to quantify the functional improvements of the foot after surgery.


Eligibility Criteria:
Inclusion Criteria:

* patients with idiopathic flat foot with indication for corrective surgical treatment according to Grice (arthrodesis of the subtalar joint)
* age between 18 and 65 years
* BMI less than 40
* signature of informed consent.

Exclusion Criteria:

* patients with severe alterations or other pathologies affecting the foot and lower limb
* severe vascular and neurological systemic diseases
* systemic diseases that can compromise bone consolidation
Does the Cerebroplacental Ratio (CPR) Predict Adverse Outcomes in Low Risk Pregnancies?

Ultrasound Doppler studies are used during pregnancy to help manage pregnancies complicated by fetal growth restriction. The cerebroplacental ratio may predict adverse outcomes in low risk pregnancies. In a prospective study, the investigators will examine whether fetuses with an abnormal CPR at or near term are at increased risk for being delivered by cesarean,

This is a multicenter prospective study of low-risk nulliparous women who will be recruited if they are having an ultrasound at 36 weeks of estimated gestational age or greater. As part of the study, women will have umbilical and middle cerebral artery Doppler studies and the CPR will be calculated by dividing the middle cerebral artery PI by the umbilical artery PI. Providers caring for study subjects will be blinded to this result. Pregnancy outcomes in women with CPR values less than the 10th percentile for gestational age will be compared to those with CPR values above the 10th percentile.

A secondary aim of the study is to analyze CPR as a continuous variable.

Eligibility Criteria:
Inclusion Criteria:

* Nulliparous pregnant women between the ages of 18 and 45 years with low risk pregnancies who present for obstetrical ultrasound at 36 weeks of gestation or later with a planned delivery at a Perinatal Research Consortium hospital.

Exclusion Criteria:

* Multifetal pregnancy at the time of presentation
* Known fetal chromosomal anomaly
* Known fetal malformation
* Preeclampsia
* Fetal growth restriction
* Multiparity
* Prior cesarean section
* Placental abnormalities such as previa or accreta
* Pregestational diabetes
* Plan to deliver outside the Perinatal Research Consortium affiliated hospitals
REBOUND PAIN AFTER PERIPHERAL NERVE BLOCKS

In recent years, the use of regional anesthesia techniques as part of multimodal analgesia strategies to maximize pain control in patients has reduced opioid requirements and promoted early mobility and rehabilitation in the perioperative period. Regional anesthesia has benefits, mainly peripheral nerve blocks (PNB), muscle relaxation, and postoperative analgesia, thus allowing for control of postoperative pain and early discharge from the hospital. In addition, using PNB techniques provides:

Hemodynamic stability. Reduced need for a post-anesthetic care unit (PACU). Reduced unplanned hospitalization for pain control. Less airway management. Reduced incidence of opioid-related adverse events. Greater patient satisfaction

The main feature of rebound pain is that it is severe pain, within 8-24 hours after PNB. It usually remains severe for 2-6 hours, but the subsequent pain trajectory is consistent with the recovery process expected at surgical intervention. Therefore, rebound pain is temporary and different from persistent post-surgical pain (PPSP).

Rebound pain often occurs at night. However, this is probably related to the 8 to 12-hour duration of most single-injection PNBs and the completion of most elective surgeries during daylight hours.

This study aims to reveal the rebound pain profile, determine the risk factors, and contribute to developing strategies that can prevent rebound pain.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged \>18 years who underwent orthopedic surgery with the peripheral nerve block

Exclusion Criteria:

* Patients who did not want to participate in the study
* dementia
* severe psychiatric or cognitive dysfunction
* coagulopathy
* neuropathic disorder
* local anesthetic allergy
* serious heart-lung disease
* chronic opioid use
Comparation of Treatment Strategies for OVF: Teriparatide Injection and PVP

This study aimed to compare teriparatide treatments and PVPs, focusing on its effects on life qualities and effect/coast ratio and evaluate which method is better for patients.

Osteoporosis and osteoporotic vertebral fracture (OVF)s are the common diseases that affect the qualities of senior people. The general treatments for OVFs including percutaneous vertebroplasty (PVP) operation and conservative treatments with pain killers. But with the widely used methods, the life quality of patients were still not satisfied. Teriparatide has been proven to increase bone qualities in patients with severe osteoporosis and reduced the fracture possibilities. The investigators' previous clinical observation found teriparatide could be applied to treat fresh OVFs.

90 participants who diagnosed fresh OVFS were included in the trial. After they received each of three kinds of interventions mentioned in this study, The investigators followed up all these cases. Once 30 cases goal reaches in a certain group, the data collection in that special will stop automatically. The quality of life, pain score and BMDs will be evaluated in certain time during the trial.

Eligibility Criteria:
Inclusion Criteria:

* 1.postmenopausal women with osteoporotic fractures 2.treated with teriparatide 3.or treated with vertebroplasty 4.or treated with teriparatide after vertebroplasty 5.or treated with Fosamax 6. willing to anticipate the trial

Exclusion Criteria:

* Serious other illness or disease which effecting quality of life occurs later in treatment
* unwilling to anticipate the trial
Anti-aging and Anti-oxidant Efficacy Evaluation of the MelaGene

The primary purpose of the present study is to evaluate the effects of MelaGene on anti-aging and anti-oxidant.


Eligibility Criteria:
Inclusion Criteria:

* 30 to 65-year-old;
* Must read and sign the informed consent form before the experiment;
* People who are willing to cooperate with contraception during the trial period;
* Do not change lifestyle and eating habits arbitrarily during the trial period;
* Do not take supplementary foods and health supplements with the same efficacy two weeks before and during the test;
* If any adverse reaction occurs during the experiment, subjects should be notified the researcher immediately.

Exclusion Criteria:

* Subject who is not willing to participate in this study;
* Vegetarians;
* People with a history of organ transplantation, epilepsy or convulsions, liver and kidney disease, malignant tumors, endocrine diseases, mental illness, alcohol or drug abuse, and other major organic diseases (according to medical history);
* Participate in other clinical trials related to antioxidants and anti-aging four weeks before and during the test;
* People with a history of dyspepsia would affect the absorption of the test product;
* Allergic to the components of the test product;
* Pregnant or breast-feeding women;
* Take anti-oxidant supplements;
* Undergoing hormone replacement therapy.
Long-Term Olanzapine Treatment in Children With Autism

This study will determine the short- and long-term safety and effectiveness of the drug olanzapine (Zyprexa®) for reducing symptoms of autism in children.

Autism is a serious childhood disorder that can significantly impair functioning and development. Educational and psychosocial programs are standard treatments for autistic children, but drug therapy is often needed as well. Haloperidol is the drug most commonly prescribed for symptoms of autism. However, long-term administration of haloperidol has been associated with adverse effects such as blurred vision, constipation, and nausea. The investigation of alternative drug treatments is necessary. This study will determine whether the antipsychotic drug olanzapine may be a safe and effective alternative to haloperidol for treating symptoms of autism in children.

This study will last 36 weeks and will comprise 2 phases. In Phase I, participants will be randomly assigned to receive either olanzapine or placebo for 12 weeks. Participants who do not respond to treatment will complete their participation in the study. Participants who respond to their assigned Phase I treatment will continue onto Phase II. All Phase II participants will receive olanzapine daily for 6 months. Self-report scales and checklists will be used to assess participants after each phase; these measures will be completed by participants and their parents.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of autism
* Parent or guardian willing to provide informed consent

Exclusion Criteria:

* Uncontrolled seizure disorder
* Medical illness other than autism affecting the whole body
* Obesity
* History of psychosis
* Impairment of voluntary movement
* History of olanzapine treatment
Bristol Bladder Trial

26 patients with invasive primary transitional cell carcinoma of the bladder will receive 4 cycles of combination chemotherapy consisting of Cabazitaxel and Cisplatin both given intravenously on day 1 of each 3 weekly cycle prior to radical cystectomy, to evaluate the overall response rate and to determine whether this approach warrants further research of a phase II/III study.Participation in 2 sub studies will also be offered to the participants.

1. Contrast Magnetic resonance imaging (MRI ) scans will be taken at baseline and after cycle 1 and cycle 3.
2. A pilot sub study involving the circulating tumour cell concentration from blood samples taken at baseline, prior to each cycle of chemotherapy and prior to surgery


Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years
* Histologically confirmed primary transitional cell carcinoma (TCC) of the urinary bladder
* T2 to T4 disease, N0 M0 determined by computerised tomography (CT) imaging and biopsy or transurethral resection
* Eastern Co-operative Oncology Group (ECOG) Performance status 0 or 1
* Glomerular filtration rate (GFR) ≥60ml/min.
* Written, informed consent

Exclusion Criteria

* ECOG Performance Status ≥ 2
* Lymph node involvement or metastatic disease
* Prior surgery (except transurethral resection of bladder tumour), radiation, che-motherapy, or other anti-cancer therapy within 4 weeks prior to enrolment
* Active Grade ≥2 peripheral neuropathy
* Active secondary cancers
* History of severe hypersensitivity reaction (≥Grade 3) to polysorbate 80 containing drugs
* Other concurrent serious illness or medical conditions
* Inadequate organ function as evidenced by peripheral blood counts at enrolment:
* Electrocardiogram (ECG) evidence of uncontrolled cardiac arrhythmias, angina pectoris, and/or hypertension, history of congestive heart failure, or myocardial infarction within last 6 months.
* Uncontrolled diabetes mellitus.
* Active uncontrolled gastro-oesophageal reflux disease (GORD).
* Active infection requiring systemic antibiotic or anti-fungal medication
* Participation in another clinical trial with any investigational drug within 30 days prior to study enrolment.
* Concurrent or planned treatment with strong inhibitors of cytochrome P450 3A4/5. A 1-week washout period is necessary for patients who are already on these treatments.
* Concurrent or planned treatment with strong inducers of cytochrome P450 3A4/5. A 1-week washout period is necessary for patients who are already on these treatments.
* Contraindications to cisplatin.
* Patient with reproductive potential not implementing an accepted and effective method of contraception.